Walgreens Boots Alliance (WBA) Price Target Increased to $80.00 by Analysts at Barclays

Share on StockTwits

Walgreens Boots Alliance (NASDAQ:WBA) had its price objective upped by Barclays from $77.00 to $80.00 in a research report released on Friday. Barclays currently has an equal weight rating on the pharmacy operator’s stock.

A number of other brokerages have also weighed in on WBA. BidaskClub raised shares of Walgreens Boots Alliance from a buy rating to a strong-buy rating in a research note on Friday, September 28th. ValuEngine raised shares of Walgreens Boots Alliance from a sell rating to a hold rating in a research note on Friday. Citigroup lifted their price target on shares of Walgreens Boots Alliance from $69.00 to $76.00 and gave the company a neutral rating in a research note on Friday. Robert W. Baird lifted their price target on shares of Walgreens Boots Alliance from $69.00 to $71.00 and gave the company a neutral rating in a research note on Friday. Finally, Royal Bank of Canada set a $82.00 price target on shares of Walgreens Boots Alliance and gave the company an outperform rating in a research note on Monday, October 8th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of Hold and an average target price of $77.56.

WBA traded up $2.60 during trading on Friday, reaching $73.50. The company had a trading volume of 9,645,179 shares, compared to its average volume of 6,227,956. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.47 and a current ratio of 0.93. Walgreens Boots Alliance has a 12 month low of $59.07 and a 12 month high of $80.68. The firm has a market cap of $72.35 billion, a P/E ratio of 14.41, a PEG ratio of 1.11 and a beta of 1.04.

Walgreens Boots Alliance (NASDAQ:WBA) last announced its quarterly earnings results on Thursday, October 11th. The pharmacy operator reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.45 by $0.03. Walgreens Boots Alliance had a net margin of 3.36% and a return on equity of 21.22%. The firm had revenue of $33.44 billion for the quarter, compared to analyst estimates of $33.64 billion. On average, sell-side analysts anticipate that Walgreens Boots Alliance will post 5.98 earnings per share for the current fiscal year.

In other news, insider Stefano Pessina bought 1,697,438 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were acquired at an average cost of $63.92 per share, for a total transaction of $108,500,236.96. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William C. Foote sold 2,736 shares of the business’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $65.99, for a total transaction of $180,548.64. Following the transaction, the director now owns 10,943 shares in the company, valued at $722,128.57. The disclosure for this sale can be found here. Insiders own 14.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of WBA. BlueMountain Capital Management LLC acquired a new position in shares of Walgreens Boots Alliance in the second quarter valued at $103,000. CSat Investment Advisory L.P. acquired a new position in shares of Walgreens Boots Alliance in the second quarter valued at $104,000. Squar Milner Financial Services LLC acquired a new position in shares of Walgreens Boots Alliance in the second quarter valued at $106,000. Kaizen Advisory LLC increased its holdings in shares of Walgreens Boots Alliance by 128.6% in the second quarter. Kaizen Advisory LLC now owns 1,925 shares of the pharmacy operator’s stock valued at $116,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Camarda Financial Advisors LLC acquired a new position in shares of Walgreens Boots Alliance in the second quarter valued at $137,000. Institutional investors and hedge funds own 61.92% of the company’s stock.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

Featured Article: Market Capitalization and Individual Investors

Analyst Recommendations for Walgreens Boots Alliance (NASDAQ:WBA)

Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Walgreens Boots Alliance  Price Target Increased to $80.00 by Analysts at Barclays
Walgreens Boots Alliance Price Target Increased to $80.00 by Analysts at Barclays
Home Bancorp  Rating Lowered to Hold at Zacks Investment Research
Home Bancorp Rating Lowered to Hold at Zacks Investment Research
Kaiser Aluminum  Downgraded to “Hold” at BidaskClub
Kaiser Aluminum Downgraded to “Hold” at BidaskClub
Zacks: Brokerages Set $5.60 Target Price for OpGen Inc
Zacks: Brokerages Set $5.60 Target Price for OpGen Inc
Zacks: Analysts Expect Seabridge Gold Inc  to Announce -$0.05 Earnings Per Share
Zacks: Analysts Expect Seabridge Gold Inc to Announce -$0.05 Earnings Per Share
Morgan Stanley Cuts Microchip Technology  Price Target to $75.00
Morgan Stanley Cuts Microchip Technology Price Target to $75.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.